Related Experiment Videos
Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series.
D Bienfang1, J S Coblyn, M H Liang
1Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, and Robert B. Brigham Multipurpose Arthritis and Musculoskeletal Disease Center, Boston, Massachusetts, USA.
The Journal of Rheumatology
|November 28, 2000
Summary
Hydroxychloroquine retinopathy can occur even with normal kidney function, regardless of total dosage. Early symptoms include central vision changes, and the condition may worsen after discontinuing hydroxychloroquine (HCQ).
Area of Science:
- Ophthalmology
- Rheumatology
- Pharmacology
Background:
- Hydroxychloroquine (HCQ) is a widely used medication for autoimmune conditions.
- HCQ retinopathy is a known, potentially sight-threatening side effect.
- Understanding the risk factors and clinical presentation is crucial for early detection.
Observation:
- This study reviewed a series of patients diagnosed with HCQ retinopathy.
- Clinical features were analyzed to identify key diagnostic and prognostic indicators.
- The series highlights specific patient presentations and outcomes.
Findings:
- HCQ retinopathy can occur in patients with normal renal function, irrespective of cumulative dosage.
- Color vision testing is a critical diagnostic tool for detecting early retinopathy.
- Altered central vision is the most common initial symptom reported by affected patients.
- A normal-appearing optic fundus does not rule out the presence of HCQ retinopathy.
- Retinopathy progression can continue even after HCQ treatment cessation.
Implications:
- Ophthalmologists and rheumatologists must maintain a high index of suspicion for HCQ retinopathy.
- Regular monitoring with color vision testing is essential for patients on long-term HCQ therapy.
- Patient education regarding visual symptoms is vital for prompt reporting and intervention.